In Section C, members will acquire ABBV-744 and oral navitoclax. In Phase D, members will get ABBV-744 and ruxolitinib. Members will obtain treatment right until illness progression or even the individuals are not able to tolerate the study drugs. Ubiquitin-related proteins that control The soundness of crucial super enhancer-mediated proteins https://adama221lwg3.wikipresses.com/user